As of the Year 2022, Therapeutic antibodies [multi-faceted proteins] have become the predominant class of new drugs positively impacting patients across the globe for treating several human diseases including cancer, autoimmune, and infectious diseases. This has influenced post Pandemic Research in Biopharma Companies for antibody therapy development from bench to bedside. Due to their high degree of specificity and generally favourable safety profiles, monoclonal antibodies have also emerged as one of the most promising and fastest growing classes of bio therapeutics. There are currently over 70 FDA-approved monoclonal antibodies and several hundred more in clinical development. We will highlight cutting edge technological and clinical advancements of interest also to a broad spectrum of Industry professionals, scientists & researchers here.
- This event has passed.